de State Street Vertex Pharmaceuticals VRTX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 5897 M | Comprar |
11,871,459
+141,320
| +1% | +USD 62.6 M | 0.17% | 96 |
|
|
2026
Q1 | USD 5238 M | Comprar |
11,730,139
+40,600
| +0.3% | +USD 18.9 M | 0.18% | 99 |
|
|
2025
Q4 | USD 5300 M | Comprar |
11,689,539
+83,539
| +0.7% | +USD 36 M | 0.18% | 99 |
|
|
2025
Q3 | USD 4545 M | Vender |
11,606,000
-169,227
| -1% | -USD 70.7 M | 0.16% | 110 |
|
|
2025
Q2 | USD 5242 M | Vender |
11,775,227
-13,430
| -0.1% | -USD 6.19 M | 0.2% | 101 |
|
|
2025
Q1 | USD 5715 M | Vender |
11,788,657
-190,748
| -2% | -USD 88.9 M | 0.24% | 82 |
|
|
2024
Q4 | USD 4824 M | Comprar |
11,979,405
+163,156
| +1% | +USD 75.6 M | 0.19% | 95 |
|
|
2024
Q3 | USD 5496 M | Comprar |
11,816,249
+90,173
| +0.8% | +USD 43.3 M | 0.22% | 79 |
|
|
2024
Q2 | USD 5496 M | Vender |
11,726,076
-280,407
| -2% | -USD 122 M | 0.24% | 74 |
|
|
2024
Q1 | USD 5019 M | Vender |
12,006,483
-77,335
| -0.6% | -USD 32.7 M | 0.22% | 84 |
|
|
2023
Q4 | USD 4917 M | Comprar |
12,083,818
+44,272
| +0.4% | +USD 16.4 M | 0.24% | 77 |
|
|
2023
Q3 | USD 4187 M | Vender |
12,039,546
-292,047
| -2% | -USD 102 M | 0.23% | 83 |
|
|
2023
Q2 | USD 4340 M | Comprar |
12,331,593
+124,141
| +1% | +USD 41.8 M | 0.23% | 84 |
|
|
2023
Q1 | USD 3846 M | Vender |
12,207,452
-162,978
| -1% | -USD 48.9 M | 0.22% | 95 |
|
|
2022
Q4 | USD 3572 M | Comprar |
12,370,430
+75,639
| +0.6% | +USD 23.1 M | 0.21% | 98 |
|
|
2022
Q3 | USD 3560 M | Comprar |
12,294,791
+30,742
| +0.3% | +USD 8.85 M | 0.23% | 88 |
|
|
2022
Q2 | USD 3456 M | Comprar |
12,264,049
+211,286
| +2% | +USD 56.6 M | 0.21% | 94 |
|
|
2022
Q1 | USD 3145 M | Vender |
12,052,763
-304,152
| -2% | -USD 72.2 M | 0.16% | 127 |
|
|
2021
Q4 | USD 2714 M | Comprar |
12,356,915
+33,499
| +0.3% | +USD 6.51 M | 0.13% | 143 |
|
|
2021
Q3 | USD 2235 M | Comprar |
12,323,416
+617,593
| +5% | +USD 121 M | 0.12% | 156 |
|
|
2021
Q2 | USD 2360 M | Comprar |
11,705,823
+530,785
| +5% | +USD 111 M | 0.12% | 155 |
|
|
2021
Q1 | USD 2401 M | Vender |
11,175,038
-261,026
| -2% | -USD 57.3 M | 0.14% | 137 |
|
|
2020
Q4 | USD 2703 M | Comprar |
11,436,064
+74,118
| +0.7% | +USD 17 M | 0.17% | 115 |
|
|
2020
Q3 | USD 3092 M | Vender |
11,361,946
-306,299
| -3% | -USD 84.5 M | 0.21% | 90 |
|
|
2020
Q2 | USD 3387 M | Comprar |
11,668,245
+219,002
| +2% | +USD 59.4 M | 0.25% | 82 |
|
|
2020
Q1 | USD 2724 M | Comprar |
11,449,243
+54,718
| +0.5% | +USD 12.6 M | 0.24% | 87 |
|
|
2019
Q4 | USD 2495 M | Comprar |
11,394,525
+80,917
| +0.7% | +USD 16.4 M | 0.17% | 119 |
|
|
2019
Q3 | USD 1917 M | Vender |
11,313,608
-60,634
| -0.5% | -USD 10.7 M | 0.14% | 158 |
|
|
2019
Q2 | USD 2086 M | Vender |
11,374,242
-109,804
| -1% | -USD 19.2 M | 0.16% | 133 |
|
|
2019
Q1 | USD 2112 M | Comprar |
11,484,046
+643,769
| +6% | +USD 119 M | 0.16% | 120 |
|
|
2018
Q4 | USD 1796 M | Vender |
10,840,277
-53,978
| -0.5% | -USD 9.35 M | 0.16% | 128 |
|
|
2018
Q3 | USD 2100 M | Comprar |
10,894,255
+404,711
| +4% | +USD 72.1 M | 0.16% | 126 |
|
|
2018
Q2 | USD 1783 M | Comprar |
10,489,544
+455,166
| +5% | +USD 70.6 M | 0.15% | 137 |
|
|
2018
Q1 | USD 1635 M | Vender |
10,034,378
-941,685
| -9% | -USD 154 M | 0.14% | 147 |
|
|
2017
Q4 | USD 1645 M | Vender |
10,976,063
-242,464
| -2% | -USD 35.9 M | 0.13% | 155 |
|
|
2017
Q3 | USD 1706 M | Vender |
11,218,527
-140,623
| -1% | -USD 21.2 M | 0.15% | 145 |
|
|
2017
Q2 | USD 1464 M | Vender |
11,359,150
-654,028
| -5% | -USD 78.7 M | 0.13% | 168 |
|
|
2017
Q1 | USD 1314 M | Comprar |
12,013,178
+239,017
| +2% | +USD 21 M | 0.12% | 184 |
|
|
2016
Q4 | USD 867 M | Comprar |
11,774,161
+308,574
| +3% | +USD 25.1 M | 0.08% | 259 |
|
|
2016
Q3 | USD 1000 M | Comprar |
11,465,587
+1,639,879
| +17% | +USD 155 M | 0.1% | 223 |
|
|
2016
Q2 | USD 845 M | Comprar |
9,825,708
+35,700
| +0.4% | +USD 3.08 M | 0.09% | 244 |
|
|
2016
Q1 | USD 778 M | Vender |
9,790,008
-11,572
| -0.1% | -USD 1.05 M | 0.08% | 251 |
|
|
2015
Q4 | USD 1233 M | Comprar |
9,801,580
+130,364
| +1% | +USD 15.7 M | 0.13% | 156 |
|
|
2015
Q3 | USD 1007 M | Comprar |
9,671,216
+20,073
| +0.2% | +USD 2.58 M | 0.12% | 187 |
|
|
2015
Q2 | USD 1192 M | Vender |
9,651,143
-301,592
| -3% | -USD 38 M | 0.13% | 171 |
|
|
2015
Q1 | USD 1174 M | Vender |
9,952,735
-303,130
| -3% | -USD 36.3 M | 0.12% | 183 |
|
|
2014
Q4 | USD 1218 M | Comprar |
10,255,865
+502,104
| +5% | +USD 56.6 M | 0.12% | 186 |
|
|
2014
Q3 | USD 1095 M | Vender |
9,753,761
-208,163
| -2% | -USD 19.8 M | 0.12% | 186 |
|
|
2014
Q2 | USD 943 M | Vender |
9,961,924
-132,443
| -1% | -USD 9.29 M | 0.1% | 205 |
|
|
2014
Q1 | USD 714 M | Comprar |
10,094,367
+457,444
| +5% | +USD 36.2 M | 0.08% | 248 |
|
|
2013
Q4 | USD 716 M | Comprar |
9,636,923
+365,348
| +4% | +USD 25.4 M | 0.08% | 247 |
|
|
2013
Q3 | USD 703 M | Comprar |
9,271,575
+2,192,814
| +31% | +USD 174 M | 0.09% | 233 |
|
|
2013
Q2 | USD 565 M | Comprar |
+7,078,761
| Nuevas | +USD 521 M | 0.07% | 279 |
|
Otros fondos que tienen VRTX en su cartera
Posición de State Street en VRTX: resumen de T2 2026
State Street aumentó su participación en Vertex Pharmaceuticals (VRTX) en 1.2% durante T2 2026, al comprar aproximadamente USD 62.6 M y elevar la posición a 11,871,459 acciones con un valor de USD 5897 M. La posición representa 0.17% de la cartera y ocupa el puesto #96.
State Street reportó por primera vez una posición en VRTX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 1,765 fondos que sigue Wall St. Rank mantienen una posición en VRTX.
- Al cierre de T2 2026, State Street tenía 11,871,459 acciones de Vertex Pharmaceuticals con un valor de USD 5897 M.
- State Street compró 141,320 acciones de Vertex Pharmaceuticals en T2 2026, por un monto estimado de USD 62.6 M.
- Vertex Pharmaceuticals representó 0.17% de la cartera de State Street en T2 2026 y fue su posición número 96.
- State Street reportó por primera vez una posición en Vertex Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 1,765 fondos que sigue Wall St. Rank tenían Vertex Pharmaceuticals en cartera.
Según el Informe 13F de State Street correspondiente a T2 2026, presentado el 7 ago 2026.